Morningstar

Astellas Pharma Inc 4503

Stock XTKS Rating as of Oct 1, 2026

News

New Preliminary Real-World VEOZAH™ (fezolinetant) Data Highlights Improvements in Menopause-Related Symptoms and Sleep Outcomes

PR Newswire Oct 2, 2026, 12:00:00 PM
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

PR Newswire Sep 23, 2026, 11:30:00 PM
Astellas enters voluntary agreement with U.S. government supporting affordable access to medicines

PR Newswire Aug 31, 2026, 10:00:00 PM
Astellas Doses First Patient in Phase 3 Study of ASP2138 in CLDN18.2-postive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

PR Newswire Aug 24, 2026, 11:30:00 PM
Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA

Global News Select Jul 10, 2026, 6:56:00 PM
Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer

Global News Select Apr 20, 2026, 11:44:00 AM
Merck, Pfizer Report Positive Results From Combined Bladder-Cancer Trial

Global News Select Feb 27, 2026, 3:43:00 PM
Vir Biotechnology, Astellas in $335 Million Licensing Deal for Prostate Cancer Treatment

Global News Select Feb 23, 2026, 11:17:00 PM
'Women deserve an apology': For menopause, hormone therapy is now considered safe - just in time for aging millennials

MarketWatch Jan 8, 2026, 12:14:00 PM
Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study

Global News Select Dec 17, 2025, 12:53:00 PM
FDA Approves Merck's Keytruda with Padcev to Treat Bladder Cancer — Update

Global News Select Nov 21, 2025, 7:19:00 PM
FDA Approves Merck's Keytruda with Astellas's Padcev to Treat Bladder Cancer

Global News Select Nov 21, 2025, 6:07:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.